Wondering if ANI Pharmaceuticals could be the undervalued gem you’ve been searching for? You’re not alone, as the buzz around its stock price has plenty of investors rethinking its true value.

The share price has surged 53.0% year-to-date and 48.3% over the past year, but recent weeks brought a 7.7% pullback. This highlights both its growth potential and shifting market sentiment.

Several headlines have kept ANI Pharmaceuticals in the spotlight, including positive developments in its specialty pharmaceutical pipeline and announcements about strategic partnerships. This news likely fueled that substantial rally, but may also explain recent volatility as investors process what comes next.

Our initial valuation score for ANI…